JP2008519850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519850A5 JP2008519850A5 JP2007541357A JP2007541357A JP2008519850A5 JP 2008519850 A5 JP2008519850 A5 JP 2008519850A5 JP 2007541357 A JP2007541357 A JP 2007541357A JP 2007541357 A JP2007541357 A JP 2007541357A JP 2008519850 A5 JP2008519850 A5 JP 2008519850A5
- Authority
- JP
- Japan
- Prior art keywords
- morpholin
- group
- pyrimidine
- carboxylic acid
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 179
- -1 azuleneyl group Chemical group 0.000 claims 117
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000004122 cyclic group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 239000004202 carbamide Substances 0.000 claims 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- LCOWRLHONNLEGJ-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxylic acid Chemical compound N=1C(N2CCOCC2)=NC(C(=O)O)=CC=1OCCN1CCOCC1 LCOWRLHONNLEGJ-UHFFFAOYSA-N 0.000 claims 7
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 7
- NEFAZJJIHDDXKM-UHFFFAOYSA-N 2,3-dimethyl-1h-indol-5-amine Chemical compound C1=C(N)C=C2C(C)=C(C)NC2=C1 NEFAZJJIHDDXKM-UHFFFAOYSA-N 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 4
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 102000013462 Interleukin-12 Human genes 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- OOGPQRKICJQUCD-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxylic acid Chemical compound N=1C(N2CCOCC2)=NC(C(=O)O)=CC=1OCCC1=CC=CC=N1 OOGPQRKICJQUCD-UHFFFAOYSA-N 0.000 claims 2
- LGLNAQMPBACCGH-UHFFFAOYSA-N 2-morpholin-4-yl-6-[2-(2-oxo-1,3-oxazolidin-3-yl)ethoxy]pyrimidine-4-carboxylic acid Chemical compound N=1C(N2CCOCC2)=NC(C(=O)O)=CC=1OCCN1CCOC1=O LGLNAQMPBACCGH-UHFFFAOYSA-N 0.000 claims 2
- IFGCXSGJDCYJNX-UHFFFAOYSA-N 3-ethyl-1h-indol-5-amine Chemical compound C1=C(N)C=C2C(CC)=CNC2=C1 IFGCXSGJDCYJNX-UHFFFAOYSA-N 0.000 claims 2
- POYRLWQLOUUKAY-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-carbazol-3-amine Chemical compound C1CCCC2=C1NC1=CC=C(N)C=C12 POYRLWQLOUUKAY-UHFFFAOYSA-N 0.000 claims 2
- 206010065687 Bone loss Diseases 0.000 claims 2
- 239000005973 Carvone Substances 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 230000019734 interleukin-12 production Effects 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- NNRKUPYMNLJXNI-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-4,6-dimorpholin-4-ylpyridine-2-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCOCC2)=CC=1N1CCOCC1 NNRKUPYMNLJXNI-UHFFFAOYSA-N 0.000 claims 2
- BWSJGVKBSXUMMB-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-morpholin-4-yl-4-(2-morpholin-4-ylethoxy)pyridine-2-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=C(C=1)N2CCOCC2)=CC=1OCCN1CCOCC1 BWSJGVKBSXUMMB-UHFFFAOYSA-N 0.000 claims 2
- GNLBVDDEICCLCL-UHFFFAOYSA-N n-(3-hydroxyphenyl)-n'-[2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]oxamide Chemical compound OC1=CC=CC(NC(=O)C(=O)NC=2N=C(N=C(OCCC=3N=CC=CC=3)C=2)N2CCOCC2)=C1 GNLBVDDEICCLCL-UHFFFAOYSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 210000002997 osteoclast Anatomy 0.000 claims 2
- 238000012261 overproduction Methods 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000005888 tetrahydroindolyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- GBVGWHPVQBIKLE-UHFFFAOYSA-N 1-(1h-indol-5-yl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C=1C=C2NC=CC2=CC=1NC(=O)NC(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 GBVGWHPVQBIKLE-UHFFFAOYSA-N 0.000 claims 1
- FWMOXLJYNWIVRP-UHFFFAOYSA-N 1-(2,3-dimethyl-1h-indol-5-yl)-3-(6-methyl-2-morpholin-4-ylpyrimidin-4-yl)urea Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)NC(N=1)=CC(C)=NC=1N1CCOCC1 FWMOXLJYNWIVRP-UHFFFAOYSA-N 0.000 claims 1
- KYODIFDANBIVQB-UHFFFAOYSA-N 1-(2,3-dimethyl-1h-indol-5-yl)-3-[2-morpholin-4-yl-6-(4-pyridin-2-ylpiperazin-1-yl)pyrimidin-4-yl]urea Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)NC(N=1)=CC(N2CCN(CC2)C=2N=CC=CC=2)=NC=1N1CCOCC1 KYODIFDANBIVQB-UHFFFAOYSA-N 0.000 claims 1
- QRKYQZBOXFRBNS-UHFFFAOYSA-N 1-(2,3-dimethyl-1h-indol-5-yl)-3-[6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidin-4-yl]urea Chemical compound N=1C(N(C)CCOC)=CC(NC(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 QRKYQZBOXFRBNS-UHFFFAOYSA-N 0.000 claims 1
- PKWMWKYGWUUYBT-UHFFFAOYSA-N 1-(2-bromo-4-methylphenyl)-3-[6-morpholin-4-yl-2-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]thiourea Chemical compound BrC1=CC(C)=CC=C1NC(=S)NC1=CC(N2CCOCC2)=NC(OCCN2CCOCC2)=N1 PKWMWKYGWUUYBT-UHFFFAOYSA-N 0.000 claims 1
- QDMQAJNKLTUTTP-UHFFFAOYSA-N 1-(2-chlorophenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound ClC1=CC=CC=C1NC(=O)NC1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 QDMQAJNKLTUTTP-UHFFFAOYSA-N 0.000 claims 1
- AXNDSTYKVKENSU-UHFFFAOYSA-N 1-(2-methoxyphenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound COC1=CC=CC=C1NC(=O)NC1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 AXNDSTYKVKENSU-UHFFFAOYSA-N 0.000 claims 1
- IDWOMFYXYMOQSB-UHFFFAOYSA-N 1-(2-methylquinolin-6-yl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=CC2=NC(C)=CC=C2C=C1NC(=O)NC(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 IDWOMFYXYMOQSB-UHFFFAOYSA-N 0.000 claims 1
- SXMYRLZMSMYUQG-UHFFFAOYSA-N 1-(3-ethyl-2-methyl-1h-indol-5-yl)-3-(6-methyl-2-morpholin-4-ylpyrimidin-4-yl)urea Chemical compound C1=C2C(CC)=C(C)NC2=CC=C1NC(=O)NC(N=1)=CC(C)=NC=1N1CCOCC1 SXMYRLZMSMYUQG-UHFFFAOYSA-N 0.000 claims 1
- TYICZSKYRVGROZ-UHFFFAOYSA-N 1-(3-ethyl-2-methyl-1h-indol-5-yl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethylamino)pyrimidin-4-yl]urea Chemical compound C1=C2C(CC)=C(C)NC2=CC=C1NC(=O)NC(N=C(N=1)N2CCOCC2)=CC=1NCCN1CCOCC1 TYICZSKYRVGROZ-UHFFFAOYSA-N 0.000 claims 1
- XPPCRAILQKFYIY-UHFFFAOYSA-N 1-(3-ethyl-2-methyl-1h-indol-5-yl)-3-[2-morpholin-4-yl-6-(4-pyridin-2-ylpiperazin-1-yl)pyrimidin-4-yl]urea Chemical compound C1=C2C(CC)=C(C)NC2=CC=C1NC(=O)NC(N=1)=CC(N2CCN(CC2)C=2N=CC=CC=2)=NC=1N1CCOCC1 XPPCRAILQKFYIY-UHFFFAOYSA-N 0.000 claims 1
- XGMDUACBDGDNBD-UHFFFAOYSA-N 1-(3-ethylphenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound CCC1=CC=CC(NC(=O)NC=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 XGMDUACBDGDNBD-UHFFFAOYSA-N 0.000 claims 1
- UTZLPXAPQFYMJU-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound FC1=CC=CC(NC(=O)NC=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 UTZLPXAPQFYMJU-UHFFFAOYSA-N 0.000 claims 1
- CFBIJAHDOLORFT-UHFFFAOYSA-N 1-(3-imidazol-1-ylphenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1NC(=O)NC(C=1)=CC=CC=1N1C=CN=C1 CFBIJAHDOLORFT-UHFFFAOYSA-N 0.000 claims 1
- NSAFPTQGZCKOIP-UHFFFAOYSA-N 1-(3-iodophenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound IC1=CC=CC(NC(=O)NC=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 NSAFPTQGZCKOIP-UHFFFAOYSA-N 0.000 claims 1
- WEVNAEBXRYANLY-UHFFFAOYSA-N 1-(3-methyl-2-oxo-1,3-benzothiazol-6-yl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=C2SC(=O)N(C)C2=CC=C1NC(=O)NC(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 WEVNAEBXRYANLY-UHFFFAOYSA-N 0.000 claims 1
- VHFBJCMICNRWLB-UHFFFAOYSA-N 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=C2OC(=O)N(C)C2=CC=C1NC(=O)NC(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 VHFBJCMICNRWLB-UHFFFAOYSA-N 0.000 claims 1
- NUGDENDMQYSEKH-UHFFFAOYSA-N 1-(3-methyl-4-propan-2-ylphenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=C(C)C(C(C)C)=CC=C1NC(=O)NC1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 NUGDENDMQYSEKH-UHFFFAOYSA-N 0.000 claims 1
- PTWHVGNAXHDUHU-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]urea Chemical compound CC1=CC=CC(NC(=O)NC=2N=C(N=C(OCCC=3N=CC=CC=3)C=2)N2CCOCC2)=C1 PTWHVGNAXHDUHU-UHFFFAOYSA-N 0.000 claims 1
- FATIRLHASHLSPE-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[4-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidin-2-yl]urea Chemical compound CC1=CC=CC(NC(=O)NC=2N=C(C=C(OCCC=3N=CC=CC=3)N=2)N2CCOCC2)=C1 FATIRLHASHLSPE-UHFFFAOYSA-N 0.000 claims 1
- YLURRNUCWRLBPH-UHFFFAOYSA-N 1-(4,6-dimorpholin-4-ylpyridin-2-yl)-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC=2N=C(C=C(C=2)N2CCOCC2)N2CCOCC2)=C1 YLURRNUCWRLBPH-UHFFFAOYSA-N 0.000 claims 1
- VNMXIKHVFQCNCK-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 VNMXIKHVFQCNCK-UHFFFAOYSA-N 0.000 claims 1
- BORQJTFEZSFCNQ-UHFFFAOYSA-N 1-(4-hydroxyphenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=CC(O)=CC=C1NC(=O)NC1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 BORQJTFEZSFCNQ-UHFFFAOYSA-N 0.000 claims 1
- IRKHJSXVOYOTMS-UHFFFAOYSA-N 1-(4-methylphenyl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=CC(C)=CC=C1NC(=O)NC1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 IRKHJSXVOYOTMS-UHFFFAOYSA-N 0.000 claims 1
- NBIGGIYBBGPVDU-UHFFFAOYSA-N 1-(4-methylphenyl)-3-[6-morpholin-4-yl-2-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]thiourea Chemical compound C1=CC(C)=CC=C1NC(=S)NC1=CC(N2CCOCC2)=NC(OCCN2CCOCC2)=N1 NBIGGIYBBGPVDU-UHFFFAOYSA-N 0.000 claims 1
- TURKESGUKANEJD-UHFFFAOYSA-N 1-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1NC(=O)NC(S1)=NN=C1C1CC1 TURKESGUKANEJD-UHFFFAOYSA-N 0.000 claims 1
- XEEDJKPFDDNKTA-UHFFFAOYSA-N 1-(5-hydroxynaphthalen-1-yl)-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=CC=C2C(O)=CC=CC2=C1NC(=O)NC(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 XEEDJKPFDDNKTA-UHFFFAOYSA-N 0.000 claims 1
- DYHDCKIGFFEAGK-UHFFFAOYSA-N 1-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-3-(3-propan-2-ylphenyl)urea Chemical compound CC(C)C1=CC=CC(NC(=O)NC=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 DYHDCKIGFFEAGK-UHFFFAOYSA-N 0.000 claims 1
- WRLVCELUHOKNSP-UHFFFAOYSA-N 1-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-3-(6,7,8,9-tetrahydro-5h-carbazol-3-yl)urea Chemical compound C=1C=C2NC=3CCCCC=3C2=CC=1NC(=O)NC(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 WRLVCELUHOKNSP-UHFFFAOYSA-N 0.000 claims 1
- IFBIKKSLJVOHIF-UHFFFAOYSA-N 1-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-3-phenylurea Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1NC(=O)NC1=CC=CC=C1 IFBIKKSLJVOHIF-UHFFFAOYSA-N 0.000 claims 1
- FEIFWSLXLLDKOB-UHFFFAOYSA-N 1-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-3-quinolin-5-ylurea Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)NC(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 FEIFWSLXLLDKOB-UHFFFAOYSA-N 0.000 claims 1
- ZMBHGPZBWWMLJG-UHFFFAOYSA-N 1-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)NC=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=N1 ZMBHGPZBWWMLJG-UHFFFAOYSA-N 0.000 claims 1
- WSUWPNNRWLWQOC-UHFFFAOYSA-N 1-[6-(2-hydroxy-2-methylpropoxy)-2-morpholin-4-ylpyrimidin-4-yl]-3-(3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(=O)NC=2N=C(N=C(OCC(C)(C)O)C=2)N2CCOCC2)=C1 WSUWPNNRWLWQOC-UHFFFAOYSA-N 0.000 claims 1
- LIQYKAXRYLZVAU-UHFFFAOYSA-N 1-[6-(4-acetylpiperazin-1-yl)-2-morpholin-4-ylpyrimidin-4-yl]-3-(2,3-dimethyl-1h-indol-5-yl)urea Chemical compound C1CN(C(=O)C)CCN1C1=CC(NC(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC(N2CCOCC2)=N1 LIQYKAXRYLZVAU-UHFFFAOYSA-N 0.000 claims 1
- ZKAUCEKOYUUADM-UHFFFAOYSA-N 1-[6-(4-acetylpiperazin-1-yl)-2-morpholin-4-ylpyrimidin-4-yl]-3-(3-ethyl-2-methyl-1h-indol-5-yl)urea Chemical compound C1=C2C(CC)=C(C)NC2=CC=C1NC(=O)NC(N=1)=CC(N2CCN(CC2)C(C)=O)=NC=1N1CCOCC1 ZKAUCEKOYUUADM-UHFFFAOYSA-N 0.000 claims 1
- WDSCZKGMENHGPL-UHFFFAOYSA-N 1-[6-[2-hydroxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidin-4-yl]-3-(6,7,8,9-tetrahydro-5h-carbazol-3-yl)urea Chemical compound N=1C(N(CCO)C)=CC(NC(=O)NC=2C=C3C=4CCCCC=4NC3=CC=2)=NC=1N1CCOCC1 WDSCZKGMENHGPL-UHFFFAOYSA-N 0.000 claims 1
- CDUMVVAWCAHUKI-UHFFFAOYSA-N 1-[6-morpholin-4-yl-2-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-3-naphthalen-2-ylurea Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NC(N=1)=CC(N2CCOCC2)=NC=1OCCN1CCOCC1 CDUMVVAWCAHUKI-UHFFFAOYSA-N 0.000 claims 1
- YSVUPIHDZKFEAB-UHFFFAOYSA-N 1-benzyl-3-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]urea Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1NC(=O)NCC1=CC=CC=C1 YSVUPIHDZKFEAB-UHFFFAOYSA-N 0.000 claims 1
- OMGAOBAAEGMMTF-UHFFFAOYSA-N 1-methyl-3,4-dihydro-2h-quinolin-7-amine Chemical compound C1=C(N)C=C2N(C)CCCC2=C1 OMGAOBAAEGMMTF-UHFFFAOYSA-N 0.000 claims 1
- MIMYTSWNVBMNRH-UHFFFAOYSA-N 1h-indol-6-amine Chemical compound NC1=CC=C2C=CNC2=C1 MIMYTSWNVBMNRH-UHFFFAOYSA-N 0.000 claims 1
- PYFVEIDRTLBMHG-UHFFFAOYSA-N 2,3-dimethyl-1h-indole Chemical compound C1=CC=C2C(C)=C(C)NC2=C1 PYFVEIDRTLBMHG-UHFFFAOYSA-N 0.000 claims 1
- NOYPUEHCWVCGTE-UHFFFAOYSA-N 2,3-dimethyl-n-[[2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]methyl]-1h-indol-5-amine Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NCC(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 NOYPUEHCWVCGTE-UHFFFAOYSA-N 0.000 claims 1
- PJZUZSUCXCQTMV-UHFFFAOYSA-N 2,6-dimorpholin-4-yl-n-(1,2,3-trimethylindol-5-yl)pyrimidine-4-carboxamide Chemical compound C=1C=C2N(C)C(C)=C(C)C2=CC=1NC(=O)C(N=1)=CC(N2CCOCC2)=NC=1N1CCOCC1 PJZUZSUCXCQTMV-UHFFFAOYSA-N 0.000 claims 1
- PLTAUCRWFSTPNT-UHFFFAOYSA-N 2,6-dimorpholin-4-ylpyrimidine-4-carboxylic acid Chemical compound N=1C(C(=O)O)=CC(N2CCOCC2)=NC=1N1CCOCC1 PLTAUCRWFSTPNT-UHFFFAOYSA-N 0.000 claims 1
- IDQNBVFPZMCDDN-UHFFFAOYSA-N 2-Amino-4,6-dimethylpyrimidine Chemical compound CC1=CC(C)=NC(N)=N1 IDQNBVFPZMCDDN-UHFFFAOYSA-N 0.000 claims 1
- GMJOKNFJIYHVSW-UHFFFAOYSA-N 2-[[6-[(2,3-dimethyl-1h-indol-5-yl)carbamoyl]-2-morpholin-4-ylpyrimidin-4-yl]amino]acetic acid Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(NCC(O)=O)=NC=1N1CCOCC1 GMJOKNFJIYHVSW-UHFFFAOYSA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- ONQLQLSYBGVGBX-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-(1,2,3,4-tetrahydroquinolin-7-yl)pyrimidine-4-carboxamide Chemical compound C=1C=C2CCCNC2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 ONQLQLSYBGVGBX-UHFFFAOYSA-N 0.000 claims 1
- AZBLTKDUWQEZNT-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-(1,2,3-trimethylindol-5-yl)pyrimidine-4-carboxamide Chemical compound C=1C=C2N(C)C(C)=C(C)C2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 AZBLTKDUWQEZNT-UHFFFAOYSA-N 0.000 claims 1
- BUKFMDGJPRZBRB-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-(2-pyrrolidin-1-ylpyridin-4-yl)pyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC(C=1)=CC=NC=1N1CCCC1 BUKFMDGJPRZBRB-UHFFFAOYSA-N 0.000 claims 1
- AYZRWXNXQLXLEJ-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-(3-morpholin-4-yl-1h-1,2,4-triazol-5-yl)pyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC(N1)=NN=C1N1CCOCC1 AYZRWXNXQLXLEJ-UHFFFAOYSA-N 0.000 claims 1
- FYSYXZVIPNQVFU-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-(3-morpholin-4-ylphenyl)pyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC(C=1)=CC=CC=1N1CCOCC1 FYSYXZVIPNQVFU-UHFFFAOYSA-N 0.000 claims 1
- NSAUHVTVRXALBM-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-(3-pyrazol-1-ylphenyl)pyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC(C=1)=CC=CC=1N1C=CC=N1 NSAUHVTVRXALBM-UHFFFAOYSA-N 0.000 claims 1
- GJNWFYLWACVYBB-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-(3-pyrrol-1-ylphenyl)pyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC(C=1)=CC=CC=1N1C=CC=C1 GJNWFYLWACVYBB-UHFFFAOYSA-N 0.000 claims 1
- BGHBURVYYIWSCQ-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-(3-pyrrolidin-1-ylphenyl)pyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC(C=1)=CC=CC=1N1CCCC1 BGHBURVYYIWSCQ-UHFFFAOYSA-N 0.000 claims 1
- TXWUBXYTQYQFKA-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-[3-(pyrrolidine-1-carbonyl)phenyl]pyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC(C=1)=CC=CC=1C(=O)N1CCCC1 TXWUBXYTQYQFKA-UHFFFAOYSA-N 0.000 claims 1
- ZTBKXNOCAPBSCZ-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)-n-pyridin-3-ylpyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC1=CC=CN=C1 ZTBKXNOCAPBSCZ-UHFFFAOYSA-N 0.000 claims 1
- XSPUOVGHQCROMS-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)-n-quinolin-5-ylpyrimidine-4-carboxamide Chemical compound C=1C=CC2=NC=CC=C2C=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 XSPUOVGHQCROMS-UHFFFAOYSA-N 0.000 claims 1
- CCJWNAXHCSPASW-UHFFFAOYSA-N 2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)-n-quinolin-6-ylpyrimidine-4-carboxamide Chemical compound C=1C=C2N=CC=CC2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 CCJWNAXHCSPASW-UHFFFAOYSA-N 0.000 claims 1
- VFEKBGXBINJECH-UHFFFAOYSA-N 2-morpholin-4-yl-n-naphthalen-2-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxamide Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 VFEKBGXBINJECH-UHFFFAOYSA-N 0.000 claims 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 claims 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 claims 1
- CKQHAYFOPRIUOM-UHFFFAOYSA-N 3'-Aminoacetophenone Chemical compound CC(=O)C1=CC=CC(N)=C1 CKQHAYFOPRIUOM-UHFFFAOYSA-N 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- ZJGYHZOSFFCVRS-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-yl-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]methanone Chemical compound C1CC2=CC=CC=C2CN1C(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 ZJGYHZOSFFCVRS-UHFFFAOYSA-N 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- CDKCLVKWNDKZFM-UHFFFAOYSA-N 3-n-methyl-3-n-propan-2-ylbenzene-1,3-diamine Chemical compound CC(C)N(C)C1=CC=CC(N)=C1 CDKCLVKWNDKZFM-UHFFFAOYSA-N 0.000 claims 1
- XRLIZPPQLYDPFM-UHFFFAOYSA-N 4,6-dimorpholin-4-yl-n-(1,2,3-trimethylindol-5-yl)pyridine-2-carboxamide Chemical compound C=1C=C2N(C)C(C)=C(C)C2=CC=1NC(=O)C(N=1)=CC(N2CCOCC2)=CC=1N1CCOCC1 XRLIZPPQLYDPFM-UHFFFAOYSA-N 0.000 claims 1
- OPTKUPUSLIUZRO-UHFFFAOYSA-N 4-(4-acetylpiperazin-1-yl)-n-(2,3-dimethyl-1h-indol-5-yl)-6-morpholin-4-ylpyridine-2-carboxamide Chemical compound C1CN(C(=O)C)CCN1C1=CC(N2CCOCC2)=NC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=C1 OPTKUPUSLIUZRO-UHFFFAOYSA-N 0.000 claims 1
- DGRGLKZMKWPMOH-UHFFFAOYSA-N 4-methylbenzene-1,2-diamine Chemical compound CC1=CC=C(N)C(N)=C1 DGRGLKZMKWPMOH-UHFFFAOYSA-N 0.000 claims 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 claims 1
- FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical compound CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 claims 1
- ZDQYLQYKUZMMFH-UHFFFAOYSA-N 6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-n-(3-ethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(CC)=CNC2=CC=C1NC(=O)C(N=1)=CC(N2CCC3(CC2)OCCO3)=NC=1N1CCOCC1 ZDQYLQYKUZMMFH-UHFFFAOYSA-N 0.000 claims 1
- NUJFAJKWUOKULH-UHFFFAOYSA-N 6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-n-(3-ethyl-2-methyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(CC)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCC3(CC2)OCCO3)=NC=1N1CCOCC1 NUJFAJKWUOKULH-UHFFFAOYSA-N 0.000 claims 1
- JIGZUJVJRWNIMU-UHFFFAOYSA-N 6-(2-aminoethoxy)-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(OCCN)=NC=1N1CCOCC1 JIGZUJVJRWNIMU-UHFFFAOYSA-N 0.000 claims 1
- RUNIIFULLRBHSP-UHFFFAOYSA-N 6-(4-acetylpiperazin-1-yl)-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCN1C1=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC(N2CCOCC2)=N1 RUNIIFULLRBHSP-UHFFFAOYSA-N 0.000 claims 1
- GGRAGKOFOOTGHP-UHFFFAOYSA-N 6-(4-acetylpiperazin-1-yl)-n-(3-methyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCN1C1=CC(C(=O)NC=2C=C3C(C)=CNC3=CC=2)=NC(N2CCOCC2)=N1 GGRAGKOFOOTGHP-UHFFFAOYSA-N 0.000 claims 1
- VTUXSBAOJJOMPF-UHFFFAOYSA-N 6-(4-carbamoylpiperidin-1-yl)-n-(3-ethyl-2-methyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(CC)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCC(CC2)C(N)=O)=NC=1N1CCOCC1 VTUXSBAOJJOMPF-UHFFFAOYSA-N 0.000 claims 1
- BJQWQVMKKWJOQW-UHFFFAOYSA-N 6-(4-hydroxypiperidin-1-yl)-2-morpholin-4-yl-n-(6,7,8,9-tetrahydro-5h-carbazol-3-yl)pyrimidine-4-carboxamide Chemical compound C1CC(O)CCN1C1=CC(C(=O)NC=2C=C3C=4CCCCC=4NC3=CC=2)=NC(N2CCOCC2)=N1 BJQWQVMKKWJOQW-UHFFFAOYSA-N 0.000 claims 1
- ULGGJZDYCGDHMY-UHFFFAOYSA-N 6-(4-hydroxypiperidin-1-yl)-2-morpholin-4-ylpyrimidine-4-carboxylic acid Chemical compound C1CC(O)CCN1C1=CC(C(O)=O)=NC(N2CCOCC2)=N1 ULGGJZDYCGDHMY-UHFFFAOYSA-N 0.000 claims 1
- HVOBZYSLHBVBKE-UHFFFAOYSA-N 6-(4-hydroxypiperidin-1-yl)-n-(3-methyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=CNC2=CC=C1NC(=O)C(N=1)=CC(N2CCC(O)CC2)=NC=1N1CCOCC1 HVOBZYSLHBVBKE-UHFFFAOYSA-N 0.000 claims 1
- SUAHBPVTJFNKKB-UHFFFAOYSA-N 6-(dibutylamino)-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(CCCC)CCCC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 SUAHBPVTJFNKKB-UHFFFAOYSA-N 0.000 claims 1
- HRTPGMIZASQTJY-UHFFFAOYSA-N 6-(dimethylamino)-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)C)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 HRTPGMIZASQTJY-UHFFFAOYSA-N 0.000 claims 1
- GUVSELYOFIZHNU-UHFFFAOYSA-N 6-[(2-amino-2-oxoethyl)amino]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(NCC(N)=O)=NC=1N1CCOCC1 GUVSELYOFIZHNU-UHFFFAOYSA-N 0.000 claims 1
- FMNTYNFBEIRMHA-SFHVURJKSA-N 6-[(3s)-3-acetamidopyrrolidin-1-yl]-n-(3-methyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1[C@@H](NC(=O)C)CCN1C1=CC(C(=O)NC=2C=C3C(C)=CNC3=CC=2)=NC(N2CCOCC2)=N1 FMNTYNFBEIRMHA-SFHVURJKSA-N 0.000 claims 1
- BEQUMTJBQYCRPN-UHFFFAOYSA-N 6-[2-(diethylamino)-2-oxoethoxy]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(OCC(=O)N(CC)CC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 BEQUMTJBQYCRPN-UHFFFAOYSA-N 0.000 claims 1
- PUIJEBULCTXCAH-UHFFFAOYSA-N 6-[2-(dimethylamino)ethylamino]-2-morpholin-4-ylpyrimidine-4-carboxylic acid Chemical compound CN(C)CCNC1=CC(C(O)=O)=NC(N2CCOCC2)=N1 PUIJEBULCTXCAH-UHFFFAOYSA-N 0.000 claims 1
- AAEFIZBROZKBHD-UHFFFAOYSA-N 6-[2-(methylamino)ethoxy]-2-morpholin-4-yl-n-(1,2,3-trimethylindol-5-yl)pyrimidine-4-carboxamide Chemical compound N=1C(OCCNC)=CC(C(=O)NC=2C=C3C(C)=C(C)N(C)C3=CC=2)=NC=1N1CCOCC1 AAEFIZBROZKBHD-UHFFFAOYSA-N 0.000 claims 1
- RHSLIIRIUZLVGQ-UHFFFAOYSA-N 6-[2-hydroxyethyl(methyl)amino]-2-morpholin-4-yl-n-(3-pyrazol-1-ylphenyl)pyrimidine-4-carboxamide Chemical compound N=1C(N(CCO)C)=CC(C(=O)NC=2C=C(C=CC=2)N2N=CC=C2)=NC=1N1CCOCC1 RHSLIIRIUZLVGQ-UHFFFAOYSA-N 0.000 claims 1
- YWNGFLOWZVRPNJ-UHFFFAOYSA-N 6-[2-hydroxyethyl(methyl)amino]-2-morpholin-4-yl-n-(3-pyrrol-1-ylphenyl)pyrimidine-4-carboxamide Chemical compound N=1C(N(CCO)C)=CC(C(=O)NC=2C=C(C=CC=2)N2C=CC=C2)=NC=1N1CCOCC1 YWNGFLOWZVRPNJ-UHFFFAOYSA-N 0.000 claims 1
- URWLXQVOSJICTH-UHFFFAOYSA-N 6-[2-hydroxyethyl(methyl)amino]-2-morpholin-4-yl-n-(3-pyrrolidin-1-ylphenyl)pyrimidine-4-carboxamide Chemical compound N=1C(N(CCO)C)=CC(C(=O)NC=2C=C(C=CC=2)N2CCCC2)=NC=1N1CCOCC1 URWLXQVOSJICTH-UHFFFAOYSA-N 0.000 claims 1
- OECJLIGIYDNCBS-UHFFFAOYSA-N 6-[2-hydroxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxylic acid Chemical compound OCCN(C)C1=CC(C(O)=O)=NC(N2CCOCC2)=N1 OECJLIGIYDNCBS-UHFFFAOYSA-N 0.000 claims 1
- YIUYVRIMINHGRE-UHFFFAOYSA-N 6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-yl-n-(3-propan-2-ylphenyl)pyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(C=CC=2)C(C)C)=NC=1N1CCOCC1 YIUYVRIMINHGRE-UHFFFAOYSA-N 0.000 claims 1
- PDVWVQGPKDPMCD-UHFFFAOYSA-N 6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-yl-n-(3-pyrazol-1-ylphenyl)pyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(C=CC=2)N2N=CC=C2)=NC=1N1CCOCC1 PDVWVQGPKDPMCD-UHFFFAOYSA-N 0.000 claims 1
- UUQWQRMUTRSWBY-UHFFFAOYSA-N 6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-yl-n-(3-quinoxalin-2-ylphenyl)pyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C3C=CC=CC3=NC=2)=NC=1N1CCOCC1 UUQWQRMUTRSWBY-UHFFFAOYSA-N 0.000 claims 1
- YQYQWFMKCNIOJW-UHFFFAOYSA-N 6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-yl-n-[3-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(OC(F)(F)F)C=CC=2)=NC=1N1CCOCC1 YQYQWFMKCNIOJW-UHFFFAOYSA-N 0.000 claims 1
- DDRVSEQVVDFVAG-UHFFFAOYSA-N 6-[2-methoxyethyl(methyl)amino]-n-(1-methyl-2,3-dihydroindol-6-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C3N(C)CCC3=CC=2)=NC=1N1CCOCC1 DDRVSEQVVDFVAG-UHFFFAOYSA-N 0.000 claims 1
- XZBHZJRSDQNRHO-UHFFFAOYSA-N 6-[2-methoxyethyl(methyl)amino]-n-(3-methyl-1,2-thiazol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2SN=C(C)C=2)=NC=1N1CCOCC1 XZBHZJRSDQNRHO-UHFFFAOYSA-N 0.000 claims 1
- VBHXXKKJNIZERK-UHFFFAOYSA-N 6-[2-methoxyethyl(methyl)amino]-n-[3-(2-methyl-1,3-thiazol-4-yl)phenyl]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(C)SC=2)=NC=1N1CCOCC1 VBHXXKKJNIZERK-UHFFFAOYSA-N 0.000 claims 1
- IOMWZTSDMDBYOU-UHFFFAOYSA-N 6-[2-methoxyethyl(methyl)amino]-n-[3-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(C=CC=2)C=2ON=C(C)N=2)=NC=1N1CCOCC1 IOMWZTSDMDBYOU-UHFFFAOYSA-N 0.000 claims 1
- YVAIBLCPHDHIDD-UHFFFAOYSA-N 6-[[2-(3,4-dihydro-1h-isoquinolin-2-yl)-2-oxoethyl]amino]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(NCC(=O)N2CC3=CC=CC=C3CC2)=NC=1N1CCOCC1 YVAIBLCPHDHIDD-UHFFFAOYSA-N 0.000 claims 1
- SETRPTFFCWOHAJ-UHFFFAOYSA-N 6-[[2-(4-acetylpiperazin-1-yl)-2-oxoethyl]amino]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(=O)CNC1=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC(N2CCOCC2)=N1 SETRPTFFCWOHAJ-UHFFFAOYSA-N 0.000 claims 1
- VLGVHSMULFAYTC-UHFFFAOYSA-N 6-[[2-(4-carbamoylpiperidin-1-yl)-2-oxoethyl]amino]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1NCC(=O)N1CCC(C(N)=O)CC1 VLGVHSMULFAYTC-UHFFFAOYSA-N 0.000 claims 1
- DPSFMBLRSSDDAW-UHFFFAOYSA-N 6-[[2-(dimethylamino)-2-oxoethyl]amino]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(NCC(=O)N(C)C)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 DPSFMBLRSSDDAW-UHFFFAOYSA-N 0.000 claims 1
- NHZNXKRRWIEZJT-UHFFFAOYSA-N 6-[[2-[butyl(methyl)amino]-2-oxoethyl]amino]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(NCC(=O)N(C)CCCC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 NHZNXKRRWIEZJT-UHFFFAOYSA-N 0.000 claims 1
- LCSCDUZYJLGUET-UHFFFAOYSA-N 6-[bis(2-hydroxyethyl)amino]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N(CCO)CCO)=NC=1N1CCOCC1 LCSCDUZYJLGUET-UHFFFAOYSA-N 0.000 claims 1
- MXSGEAWDZSCCOS-UHFFFAOYSA-N 6-[bis(2-methoxyethyl)amino]-n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(CCOC)CCOC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 MXSGEAWDZSCCOS-UHFFFAOYSA-N 0.000 claims 1
- DZWTXWPRWRLHIL-UHFFFAOYSA-N 6-methyl-1,3-benzothiazol-2-amine Chemical compound CC1=CC=C2N=C(N)SC2=C1 DZWTXWPRWRLHIL-UHFFFAOYSA-N 0.000 claims 1
- QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 claims 1
- HDQHWSMVOIIDSR-UHFFFAOYSA-N 6-morpholin-4-yl-4-(2-morpholin-4-ylethoxy)-n-(1,2,3-trimethylindol-5-yl)pyridine-2-carboxamide Chemical compound C=1C=C2N(C)C(C)=C(C)C2=CC=1NC(=O)C(N=C(C=1)N2CCOCC2)=CC=1OCCN1CCOCC1 HDQHWSMVOIIDSR-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010061728 Bone lesion Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- ZRVIHIHTDPBEDE-UHFFFAOYSA-N CCOBO Chemical compound CCOBO ZRVIHIHTDPBEDE-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030247 Oestrogen deficiency Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031240 Osteodystrophy Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027067 Paget disease of bone Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- KNZQVKRKTNIUPL-UHFFFAOYSA-N [2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]carbamic acid Chemical compound N=1C(N2CCOCC2)=NC(NC(=O)O)=CC=1OCCC1=CC=CC=N1 KNZQVKRKTNIUPL-UHFFFAOYSA-N 0.000 claims 1
- BOPHIWMCKMZBJI-UHFFFAOYSA-N [6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]carbamic acid Chemical compound N=1C(NC(=O)O)=CC(N2CCOCC2)=NC=1OCCC1=CC=CC=N1 BOPHIWMCKMZBJI-UHFFFAOYSA-N 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000016738 bone Paget disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VEZYKHULJGEOPY-UHFFFAOYSA-N ethyl 2-[6-[(2,3-dimethyl-1h-indol-5-yl)carbamoyl]-2-morpholin-4-ylpyrimidin-4-yl]oxyacetate Chemical compound N=1C(OCC(=O)OCC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 VEZYKHULJGEOPY-UHFFFAOYSA-N 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- GDTFQVWKJCCMER-UHFFFAOYSA-N indol-1-yl-[2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]methanone Chemical compound C1=CC2=CC=CC=C2N1C(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 GDTFQVWKJCCMER-UHFFFAOYSA-N 0.000 claims 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 claims 1
- IENZCGNHSIMFJE-UHFFFAOYSA-N indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=CC2=C1 IENZCGNHSIMFJE-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003704 interleukin-23 production Effects 0.000 claims 1
- 230000021547 interleukin-27 production Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- STCCMYMVDYTIFF-UHFFFAOYSA-N methyl 2-[[6-[(2,3-dimethyl-1h-indol-5-yl)carbamoyl]-2-morpholin-4-ylpyrimidin-4-yl]amino]acetate Chemical compound N=1C(NCC(=O)OC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 STCCMYMVDYTIFF-UHFFFAOYSA-N 0.000 claims 1
- FTAIWCKCBWKSRJ-UHFFFAOYSA-N methyl 2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxylate Chemical compound N=1C(N2CCOCC2)=NC(C(=O)OC)=CC=1OCCN1CCOCC1 FTAIWCKCBWKSRJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- KQFPIXQYTHNXOI-UHFFFAOYSA-N n'-(3,4-dimethylphenyl)-6-morpholin-4-yl-2-(2-morpholin-4-ylethoxy)pyrimidine-4-carbohydrazide Chemical compound C1=C(C)C(C)=CC=C1NNC(=O)C1=CC(N2CCOCC2)=NC(OCCN2CCOCC2)=N1 KQFPIXQYTHNXOI-UHFFFAOYSA-N 0.000 claims 1
- IOBBELSMYQSAFA-UHFFFAOYSA-N n'-(3-methylphenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyridine-4-carbohydrazide Chemical compound CC1=CC=CC(NNC(=O)C=2C=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 IOBBELSMYQSAFA-UHFFFAOYSA-N 0.000 claims 1
- OZRQFGVUWOCGOO-UHFFFAOYSA-N n'-(3-methylphenyl)-2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carbohydrazide Chemical compound CC1=CC=CC(NNC(=O)C=2N=C(N=C(OCCC=3N=CC=CC=3)C=2)N2CCOCC2)=C1 OZRQFGVUWOCGOO-UHFFFAOYSA-N 0.000 claims 1
- KWWMQNGFURGCQD-UHFFFAOYSA-N n'-(3-methylphenyl)-6-morpholin-4-yl-2-(2-morpholin-4-ylethoxy)pyrimidine-4-carbohydrazide Chemical compound CC1=CC=CC(NNC(=O)C=2N=C(OCCN3CCOCC3)N=C(C=2)N2CCOCC2)=C1 KWWMQNGFURGCQD-UHFFFAOYSA-N 0.000 claims 1
- ZZCUNOIANARXSJ-UHFFFAOYSA-N n'-(3-methylphenyl)-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidine-4-carbohydrazide Chemical compound CC1=CC=CC(NNC(=O)C=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 ZZCUNOIANARXSJ-UHFFFAOYSA-N 0.000 claims 1
- WTAZXDZPRHGMLM-UHFFFAOYSA-N n-(1,2-dimethyl-3,4-dihydro-2h-quinolin-7-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C2N(C)C(C)CCC2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 WTAZXDZPRHGMLM-UHFFFAOYSA-N 0.000 claims 1
- AQLRGTAWQOGLHK-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C3OCOC3=CC=2)=NC=1N1CCOCC1 AQLRGTAWQOGLHK-UHFFFAOYSA-N 0.000 claims 1
- XHDDORXJBUCAJH-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)-2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxamide Chemical compound C=1C=C2N=CSC2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 XHDDORXJBUCAJH-UHFFFAOYSA-N 0.000 claims 1
- NGELUNNPYKRPFW-UHFFFAOYSA-N n-(1-acetyl-2,3-dihydroindol-5-yl)-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C3CCN(C3=CC=2)C(C)=O)=NC=1N1CCOCC1 NGELUNNPYKRPFW-UHFFFAOYSA-N 0.000 claims 1
- XPFKGGCPBQXNKU-UHFFFAOYSA-N n-(1-hydroxy-2,3-dimethylindol-5-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C=1C=C2N(O)C(C)=C(C)C2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 XPFKGGCPBQXNKU-UHFFFAOYSA-N 0.000 claims 1
- KGEURCGKBJXXFI-UHFFFAOYSA-N n-(1-hydroxy-2,3-dimethylindol-5-yl)-6-methyl-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C=1C=C2N(O)C(C)=C(C)C2=CC=1NC(=O)C(N=1)=CC(C)=NC=1N1CCOCC1 KGEURCGKBJXXFI-UHFFFAOYSA-N 0.000 claims 1
- BKBDBJXAGAHTGQ-UHFFFAOYSA-N n-(1-methyl-3,4-dihydro-2h-quinolin-6-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C=1C=C2N(C)CCCC2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 BKBDBJXAGAHTGQ-UHFFFAOYSA-N 0.000 claims 1
- YOQIOKILWKXTPX-UHFFFAOYSA-N n-(1h-indol-5-yl)-2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxamide Chemical compound C=1C=C2NC=CC2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 YOQIOKILWKXTPX-UHFFFAOYSA-N 0.000 claims 1
- SIOZUYJILDSIGC-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C3OCCOC3=CC=2)=NC=1N1CCOCC1 SIOZUYJILDSIGC-UHFFFAOYSA-N 0.000 claims 1
- HSLXIOCPXTVCMN-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-5-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C=1C=C2CCCC2=CC=1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 HSLXIOCPXTVCMN-UHFFFAOYSA-N 0.000 claims 1
- INHJHHBZFCTIEU-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-yl-4-oxo-1h-pyrimidine-6-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(O)=NC=1N1CCOCC1 INHJHHBZFCTIEU-UHFFFAOYSA-N 0.000 claims 1
- OSLAVSGSRUXSMB-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 OSLAVSGSRUXSMB-UHFFFAOYSA-N 0.000 claims 1
- OIZJABXFUPDSBI-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-yl-6-(2-piperidin-1-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCCCC1 OIZJABXFUPDSBI-UHFFFAOYSA-N 0.000 claims 1
- AUKZWZRXSPVXHU-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 AUKZWZRXSPVXHU-UHFFFAOYSA-N 0.000 claims 1
- LTNZANZPPUSCSB-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-yl-6-(4-pyridin-2-ylpiperazin-1-yl)pyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCN(CC2)C=2N=CC=CC=2)=NC=1N1CCOCC1 LTNZANZPPUSCSB-UHFFFAOYSA-N 0.000 claims 1
- CXDAEBQQQWNWRZ-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-2-morpholin-4-yl-6-[(2-oxo-2-pyrrolidin-1-ylethyl)amino]pyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1NCC(=O)N1CCCC1 CXDAEBQQQWNWRZ-UHFFFAOYSA-N 0.000 claims 1
- RAGHBUYWXKFJHM-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCC3(CC2)OCCO3)=NC=1N1CCOCC1 RAGHBUYWXKFJHM-UHFFFAOYSA-N 0.000 claims 1
- YTDVSMXRGUGKJM-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-(2-hydroxyethoxy)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(OCCO)=NC=1N1CCOCC1 YTDVSMXRGUGKJM-UHFFFAOYSA-N 0.000 claims 1
- ANQMRZHRZWTVJI-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-(2-hydroxyethylamino)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(NCCO)=NC=1N1CCOCC1 ANQMRZHRZWTVJI-UHFFFAOYSA-N 0.000 claims 1
- NGCVEHPDYVQJGB-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-(2-methoxyethoxy)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(OCCOC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 NGCVEHPDYVQJGB-UHFFFAOYSA-N 0.000 claims 1
- TXNJUYFVQQQGLE-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-(2-methoxyethylamino)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(NCCOC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 TXNJUYFVQQQGLE-UHFFFAOYSA-N 0.000 claims 1
- BVWFYTZAPUOBSA-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-(4-hydroxypiperidin-1-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCC(O)CC2)=NC=1N1CCOCC1 BVWFYTZAPUOBSA-UHFFFAOYSA-N 0.000 claims 1
- MUWDJWLPSSDZFP-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-(4-methylpiperazin-1-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1CN(C)CCN1C1=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC(N2CCOCC2)=N1 MUWDJWLPSSDZFP-UHFFFAOYSA-N 0.000 claims 1
- QWGWWSVALVOWIS-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-(methylamino)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(NC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 QWGWWSVALVOWIS-UHFFFAOYSA-N 0.000 claims 1
- QTXSRPUYFXOHRC-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-[2-hydroxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(CCO)C)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 QTXSRPUYFXOHRC-UHFFFAOYSA-N 0.000 claims 1
- NAHYSALBZLCFTM-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCN(CCO)CC2)=NC=1N1CCOCC1 NAHYSALBZLCFTM-UHFFFAOYSA-N 0.000 claims 1
- MRPIECYGFWHICL-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-[[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1NCC(=O)N1CCC(O)CC1 MRPIECYGFWHICL-UHFFFAOYSA-N 0.000 claims 1
- PNTFYIZITHQWHN-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-[[2-(4-methylpiperazin-1-yl)-2-oxoethyl]amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1CN(C)CCN1C(=O)CNC1=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC(N2CCOCC2)=N1 PNTFYIZITHQWHN-UHFFFAOYSA-N 0.000 claims 1
- BDDZRZHGZSNQOV-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-[methoxy(2-morpholin-4-ylethyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C=1C(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC(N2CCOCC2)=NC=1N(OC)CCN1CCOCC1 BDDZRZHGZSNQOV-UHFFFAOYSA-N 0.000 claims 1
- FMHXOOXWOIVDNB-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-methoxy-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(OC)=CC(C(=O)NC=2C=C3C(C)=C(C)NC3=CC=2)=NC=1N1CCOCC1 FMHXOOXWOIVDNB-UHFFFAOYSA-N 0.000 claims 1
- XCHIJKWVLGRPTD-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-methyl-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(C)=NC=1N1CCOCC1 XCHIJKWVLGRPTD-UHFFFAOYSA-N 0.000 claims 1
- VILZEWSRZNKKPF-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCOCC2)=NC=1OCCC1=CC=CC=N1 VILZEWSRZNKKPF-UHFFFAOYSA-N 0.000 claims 1
- GONOACJJFGDMGS-UHFFFAOYSA-N n-(2,3-dimethyl-1h-indol-5-yl)-6-morpholin-4-ylpyridine-2-carboxamide Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC=CC=1N1CCOCC1 GONOACJJFGDMGS-UHFFFAOYSA-N 0.000 claims 1
- CEEPDSKKLHHENW-UHFFFAOYSA-N n-(2,3-dimethylquinoxalin-6-yl)-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C3N=C(C)C(C)=NC3=CC=2)=NC=1N1CCOCC1 CEEPDSKKLHHENW-UHFFFAOYSA-N 0.000 claims 1
- VRUNVFRTCGLUGG-UHFFFAOYSA-N n-(2,5-diethoxy-4-morpholin-4-ylphenyl)-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound CCOC=1C=C(NC(=O)C=2N=C(N=C(C=2)N(C)CCOC)N2CCOCC2)C(OCC)=CC=1N1CCOCC1 VRUNVFRTCGLUGG-UHFFFAOYSA-N 0.000 claims 1
- OWNHAPSAPRZUOI-UHFFFAOYSA-N n-(2-acetamidophenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound CC(=O)NC1=CC=CC=C1NC(=O)C1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 OWNHAPSAPRZUOI-UHFFFAOYSA-N 0.000 claims 1
- ZSVHKWNLOCPWSL-UHFFFAOYSA-N n-(2-chloropyridin-4-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=NC(Cl)=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 ZSVHKWNLOCPWSL-UHFFFAOYSA-N 0.000 claims 1
- BPEBMHYTKLSLAL-UHFFFAOYSA-N n-(2-methoxy-5-methylphenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound COC1=CC=C(C)C=C1NC(=O)C1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 BPEBMHYTKLSLAL-UHFFFAOYSA-N 0.000 claims 1
- APZJGOBXSUZDIO-UHFFFAOYSA-N n-(2-methyl-1,2,3,4-tetrahydroquinolin-7-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C2NC(C)CCC2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 APZJGOBXSUZDIO-UHFFFAOYSA-N 0.000 claims 1
- UHAMTLRTSURSMP-UHFFFAOYSA-N n-(2-methyl-1,3-dioxoisoindol-5-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C2C(=O)N(C)C(=O)C2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCN1CCOCC1 UHAMTLRTSURSMP-UHFFFAOYSA-N 0.000 claims 1
- DGCPUEGADGYFMX-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2,6-dimorpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C(C)C(C)=CC=C1NC(=O)C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 DGCPUEGADGYFMX-UHFFFAOYSA-N 0.000 claims 1
- OQKAACXYHQJGJG-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C(C)C(C)=CC=C1NC(=O)C1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 OQKAACXYHQJGJG-UHFFFAOYSA-N 0.000 claims 1
- LQXIFKLFIOWBHM-UHFFFAOYSA-N n-(3-aminophenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound NC1=CC=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 LQXIFKLFIOWBHM-UHFFFAOYSA-N 0.000 claims 1
- UVSPIVSEYIORPC-UHFFFAOYSA-N n-(3-aminophenyl)-n-methylacetamide Chemical compound CC(=O)N(C)C1=CC=CC(N)=C1 UVSPIVSEYIORPC-UHFFFAOYSA-N 0.000 claims 1
- NRRDEBSSVIMAGI-UHFFFAOYSA-N n-(3-bromophenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound BrC1=CC=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 NRRDEBSSVIMAGI-UHFFFAOYSA-N 0.000 claims 1
- JMJSHQTVGAVKJV-UHFFFAOYSA-N n-(3-carbamoylphenyl)-2,6-dimorpholin-4-ylpyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=CC(NC(=O)C=2N=C(N=C(C=2)N2CCOCC2)N2CCOCC2)=C1 JMJSHQTVGAVKJV-UHFFFAOYSA-N 0.000 claims 1
- ZFAJWOOTRMMBHF-UHFFFAOYSA-N n-(3-carbamoylphenyl)-2-morpholin-4-yl-6-[2-(2-oxo-1,3-oxazolidin-3-yl)ethoxy]pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=CC(NC(=O)C=2N=C(N=C(OCCN3C(OCC3)=O)C=2)N2CCOCC2)=C1 ZFAJWOOTRMMBHF-UHFFFAOYSA-N 0.000 claims 1
- QGJFBZXGEGSUIB-UHFFFAOYSA-N n-(3-chlorophenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound ClC1=CC=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 QGJFBZXGEGSUIB-UHFFFAOYSA-N 0.000 claims 1
- ZMFNKCNBCROYIG-UHFFFAOYSA-N n-(3-ethyl-1h-indol-5-yl)-2-morpholin-4-yl-6-piperidin-1-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(CC)=CNC2=CC=C1NC(=O)C(N=1)=CC(N2CCCCC2)=NC=1N1CCOCC1 ZMFNKCNBCROYIG-UHFFFAOYSA-N 0.000 claims 1
- CTRMHDWGNLLPBC-UHFFFAOYSA-N n-(3-ethyl-1h-indol-5-yl)-6-(4-methylpiperidin-1-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(CC)=CNC2=CC=C1NC(=O)C(N=1)=CC(N2CCC(C)CC2)=NC=1N1CCOCC1 CTRMHDWGNLLPBC-UHFFFAOYSA-N 0.000 claims 1
- JTJLAZVVGPTBOH-UHFFFAOYSA-N n-(3-ethyl-2-methyl-1h-indol-5-yl)-6-(4-hydroxypiperidin-1-yl)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound C1=C2C(CC)=C(C)NC2=CC=C1NC(=O)C(N=1)=CC(N2CCC(O)CC2)=NC=1N1CCOCC1 JTJLAZVVGPTBOH-UHFFFAOYSA-N 0.000 claims 1
- ZKNBRZZJHJTEIL-UHFFFAOYSA-N n-(3-ethylphenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound CCC1=CC=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 ZKNBRZZJHJTEIL-UHFFFAOYSA-N 0.000 claims 1
- FELYMZIAAGRCQA-UHFFFAOYSA-N n-(3-hydroxyphenyl)-n'-[6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]oxamide Chemical compound OC1=CC=CC(NC(=O)C(=O)NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 FELYMZIAAGRCQA-UHFFFAOYSA-N 0.000 claims 1
- BVGWDBILMRQSRK-UHFFFAOYSA-N n-(3-methoxyphenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound COC1=CC=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 BVGWDBILMRQSRK-UHFFFAOYSA-N 0.000 claims 1
- CVPHAROCZVEDOP-UHFFFAOYSA-N n-(3-methylphenyl)-n'-[2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]oxamide Chemical compound CC1=CC=CC(NC(=O)C(=O)NC=2N=C(N=C(OCCC=3N=CC=CC=3)C=2)N2CCOCC2)=C1 CVPHAROCZVEDOP-UHFFFAOYSA-N 0.000 claims 1
- YRIVBCYPWKXWHI-UHFFFAOYSA-N n-(4,6-dimethylpyridin-2-yl)-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2N=C(C)C=C(C)C=2)=NC=1N1CCOCC1 YRIVBCYPWKXWHI-UHFFFAOYSA-N 0.000 claims 1
- AMKXUWRIJFGLSW-UHFFFAOYSA-N n-(4-anilinophenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C=1C(OCCN2CCOCC2)=NC(N2CCOCC2)=NC=1C(=O)NC(C=C1)=CC=C1NC1=CC=CC=C1 AMKXUWRIJFGLSW-UHFFFAOYSA-N 0.000 claims 1
- APGXTISLBJIZCJ-UHFFFAOYSA-N n-(4-methylpyridin-2-yl)-2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxamide Chemical compound CC1=CC=NC(NC(=O)C=2N=C(N=C(OCCC=3N=CC=CC=3)C=2)N2CCOCC2)=C1 APGXTISLBJIZCJ-UHFFFAOYSA-N 0.000 claims 1
- CYNACEYBQPTFNH-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2SC=C(N=2)C(C)(C)C)=NC=1N1CCOCC1 CYNACEYBQPTFNH-UHFFFAOYSA-N 0.000 claims 1
- ZLWYUELEEHSBFH-UHFFFAOYSA-N n-(5,6-dimethyl-1,3-benzothiazol-2-yl)-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2SC3=CC(C)=C(C)C=C3N=2)=NC=1N1CCOCC1 ZLWYUELEEHSBFH-UHFFFAOYSA-N 0.000 claims 1
- GKPZSFAOXQKHQQ-UHFFFAOYSA-N n-(5-carbamoylpyridin-2-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound N1=CC(C(=O)N)=CC=C1NC(=O)C1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 GKPZSFAOXQKHQQ-UHFFFAOYSA-N 0.000 claims 1
- JESDGWHVKMXCLF-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound O1C(C)=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=N1 JESDGWHVKMXCLF-UHFFFAOYSA-N 0.000 claims 1
- XEISHXARYBOMLY-UHFFFAOYSA-N n-(5-methyl-2-nitrophenyl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound CC1=CC=C([N+]([O-])=O)C(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 XEISHXARYBOMLY-UHFFFAOYSA-N 0.000 claims 1
- HIFMBBZUEARZFA-UHFFFAOYSA-N n-(6-methyl-1,3-benzothiazol-2-yl)-2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 HIFMBBZUEARZFA-UHFFFAOYSA-N 0.000 claims 1
- VMNPDOGVIKNSDM-UHFFFAOYSA-N n-(6-methylpyridin-3-yl)-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=NC(C)=CC=C1NC(=O)C1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 VMNPDOGVIKNSDM-UHFFFAOYSA-N 0.000 claims 1
- SGAIVXJPHFMVAW-UHFFFAOYSA-N n-(9-ethylcarbazol-2-yl)-2-morpholin-4-yl-6-(2-pyridin-2-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C2N(CC)C3=CC=CC=C3C2=CC=C1NC(=O)C(N=C(N=1)N2CCOCC2)=CC=1OCCC1=CC=CC=N1 SGAIVXJPHFMVAW-UHFFFAOYSA-N 0.000 claims 1
- RLNZPMKINQTXEQ-UHFFFAOYSA-N n-[3-(2-methylpyrimidin-4-yl)phenyl]-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound CC1=NC=CC(C=2C=C(NC(=O)C=3N=C(N=C(OCCN4CCOCC4)C=3)N3CCOCC3)C=CC=2)=N1 RLNZPMKINQTXEQ-UHFFFAOYSA-N 0.000 claims 1
- HSEDGKVUDQIODT-UHFFFAOYSA-N n-[3-(diethylamino)phenyl]-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound CCN(CC)C1=CC=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 HSEDGKVUDQIODT-UHFFFAOYSA-N 0.000 claims 1
- WGSWYQGCASIRDJ-UHFFFAOYSA-N n-[3-(dimethylamino)-4-fluorophenyl]-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(C(F)=CC=2)N(C)C)=NC=1N1CCOCC1 WGSWYQGCASIRDJ-UHFFFAOYSA-N 0.000 claims 1
- PTGFJZZQJLLOCI-UHFFFAOYSA-N n-[3-(dimethylamino)-4-methylphenyl]-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C(C)C(N(C)C)=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 PTGFJZZQJLLOCI-UHFFFAOYSA-N 0.000 claims 1
- QBFRLKWOCWTFEA-UHFFFAOYSA-N n-[3-(dimethylamino)phenyl]-2,6-dimorpholin-4-ylpyrimidine-4-carboxamide Chemical compound CN(C)C1=CC=CC(NC(=O)C=2N=C(N=C(C=2)N2CCOCC2)N2CCOCC2)=C1 QBFRLKWOCWTFEA-UHFFFAOYSA-N 0.000 claims 1
- XPHMSDLLSRSGLI-UHFFFAOYSA-N n-[3-(dimethylamino)phenyl]-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound CN(C)C1=CC=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 XPHMSDLLSRSGLI-UHFFFAOYSA-N 0.000 claims 1
- ZIQJUAKXBHRDMA-UHFFFAOYSA-N n-[3-(dimethylamino)phenyl]-6-(2-hydroxyethoxy)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound CN(C)C1=CC=CC(NC(=O)C=2N=C(N=C(OCCO)C=2)N2CCOCC2)=C1 ZIQJUAKXBHRDMA-UHFFFAOYSA-N 0.000 claims 1
- HDNMNDFZKGYSHI-UHFFFAOYSA-N n-[3-(dimethylamino)phenyl]-6-(methoxyamino)-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(NOC)=CC(C(=O)NC=2C=C(C=CC=2)N(C)C)=NC=1N1CCOCC1 HDNMNDFZKGYSHI-UHFFFAOYSA-N 0.000 claims 1
- MJSKCXPVLMZALQ-UHFFFAOYSA-N n-[3-(dimethylamino)phenyl]-6-[2-hydroxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound CN(C)C1=CC=CC(NC(=O)C=2N=C(N=C(C=2)N(C)CCO)N2CCOCC2)=C1 MJSKCXPVLMZALQ-UHFFFAOYSA-N 0.000 claims 1
- SDVNROSYPIOHNX-UHFFFAOYSA-N n-[3-(dimethylamino)phenyl]-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(C=CC=2)N(C)C)=NC=1N1CCOCC1 SDVNROSYPIOHNX-UHFFFAOYSA-N 0.000 claims 1
- AGYIZURQXROXEN-WPWMEQJKSA-N n-[3-[(e)-n-(dimethylamino)-c-methylcarbonimidoyl]phenyl]-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C=C(C=CC=2)C(\C)=N\N(C)C)=NC=1N1CCOCC1 AGYIZURQXROXEN-WPWMEQJKSA-N 0.000 claims 1
- NJBXPNGPYPRMKG-UHFFFAOYSA-N n-[3-methyl-4-(methylamino)phenyl]-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C(C)C(NC)=CC=C1NC(=O)C1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 NJBXPNGPYPRMKG-UHFFFAOYSA-N 0.000 claims 1
- BSUXBHAEFFCEIN-UHFFFAOYSA-N n-[4-(dimethylamino)-3-methylphenyl]-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C(C)C(N(C)C)=CC=C1NC(=O)C1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 BSUXBHAEFFCEIN-UHFFFAOYSA-N 0.000 claims 1
- GKCHMNBULQIVFC-UHFFFAOYSA-N n-[4-(dimethylamino)phenyl]-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)C1=CC(OCCN2CCOCC2)=NC(N2CCOCC2)=N1 GKCHMNBULQIVFC-UHFFFAOYSA-N 0.000 claims 1
- YWURXFAWBJBTEP-UHFFFAOYSA-N n-[4-methyl-3-(methylamino)phenyl]-2-morpholin-4-yl-6-(2-morpholin-4-ylethoxy)pyrimidine-4-carboxamide Chemical compound C1=C(C)C(NC)=CC(NC(=O)C=2N=C(N=C(OCCN3CCOCC3)C=2)N2CCOCC2)=C1 YWURXFAWBJBTEP-UHFFFAOYSA-N 0.000 claims 1
- QMBWDIQJNTYCFK-UHFFFAOYSA-N n-[5,7-bis(trifluoromethyl)-1,8-naphthyridin-2-yl]-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2N=C3N=C(C=C(C3=CC=2)C(F)(F)F)C(F)(F)F)=NC=1N1CCOCC1 QMBWDIQJNTYCFK-UHFFFAOYSA-N 0.000 claims 1
- UHUDOWIVWUVNFG-UHFFFAOYSA-N n-[5-(dimethylamino)-2-fluorophenyl]-6-[2-methoxyethyl(methyl)amino]-2-morpholin-4-ylpyrimidine-4-carboxamide Chemical compound N=1C(N(C)CCOC)=CC(C(=O)NC=2C(=CC=C(C=2)N(C)C)F)=NC=1N1CCOCC1 UHUDOWIVWUVNFG-UHFFFAOYSA-N 0.000 claims 1
- ZEVFZRGXQXCNOK-UHFFFAOYSA-N n-[6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]-1h-indole-5-carboxamide Chemical compound C=1C=C2NC=CC2=CC=1C(=O)NC(N=1)=CC(N2CCOCC2)=NC=1OCCC1=CC=CC=N1 ZEVFZRGXQXCNOK-UHFFFAOYSA-N 0.000 claims 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 1
- KFXDYZXVIHNBFD-UHFFFAOYSA-N tetrahydrothiopyranyl sulfone group Chemical group S1C(CCCC1)S(=O)(=O)C1SCCCC1 KFXDYZXVIHNBFD-UHFFFAOYSA-N 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 claims 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- XIMZCDCRNJBKNO-UHFFFAOYSA-N CC(C1)=CC=CC1C=O Chemical compound CC(C1)=CC=CC1C=O XIMZCDCRNJBKNO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62676104P | 2004-11-10 | 2004-11-10 | |
| PCT/US2005/040952 WO2006053227A2 (en) | 2004-11-10 | 2005-11-10 | Il-12 modulatory compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519850A JP2008519850A (ja) | 2008-06-12 |
| JP2008519850A5 true JP2008519850A5 (enExample) | 2009-01-15 |
Family
ID=36337261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007541357A Pending JP2008519850A (ja) | 2004-11-10 | 2005-11-10 | Ｉｌ−１２調節化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7696202B2 (enExample) |
| EP (1) | EP1819341A4 (enExample) |
| JP (1) | JP2008519850A (enExample) |
| AU (1) | AU2005304393B2 (enExample) |
| CA (1) | CA2586870A1 (enExample) |
| TW (1) | TW200628159A (enExample) |
| WO (1) | WO2006053227A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| AU2004289305A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Heteroaryl-Hydrazone compounds |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| AU2005304393B2 (en) * | 2004-11-10 | 2012-09-27 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| TW200628463A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| CA2587590A1 (en) * | 2004-11-19 | 2006-06-08 | Synta Pharmaceuticals Corp. | Pyrimidine compounds and uses thereof |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US20070037865A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| TW200804307A (en) * | 2005-10-27 | 2008-01-16 | Synta Pharmaceuticals Corp | Process for preparing mesylate salts of IL-12 inhibitory compounds |
| WO2007071752A2 (en) | 2005-12-21 | 2007-06-28 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| US20110034454A1 (en) * | 2006-01-11 | 2011-02-10 | Allan Paul Dishington | Morpholino pyrimidine derivatives and their use in therapy |
| GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| KR20080109918A (ko) | 2006-04-11 | 2008-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물 |
| UA95298C2 (ru) | 2006-07-07 | 2011-07-25 | Бьёрингер Ингельхайм Интернациональ Гмбх | Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств |
| EP1882475A1 (en) * | 2006-07-26 | 2008-01-30 | Novartis AG | Method of treating disorders mediated by the fibroblast growth factor receptor |
| EP2057129A1 (en) * | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2008023159A1 (en) * | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| US8822497B2 (en) | 2007-03-01 | 2014-09-02 | Novartis Ag | PIM kinase inhibitors and methods of their use |
| AU2012202993B2 (en) * | 2007-03-01 | 2015-06-25 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
| TW200918542A (en) | 2007-06-20 | 2009-05-01 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| EP2176238B1 (en) * | 2007-07-09 | 2012-04-18 | AstraZeneca AB | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| AU2008279776B2 (en) * | 2007-07-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| KR20100075631A (ko) | 2007-10-11 | 2010-07-02 | 버텍스 파마슈티칼스 인코포레이티드 | 전압개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드 |
| JP5436434B2 (ja) | 2007-10-11 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なアミド |
| AU2008310660A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| CA2704336A1 (en) * | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
| RU2460525C2 (ru) * | 2008-01-04 | 2012-09-10 | Эл Джи Лайф Сайенсиз Лтд. | Производные индола и индазола, обладающие консервирующим действием по отношению к клеткам, тканям и органам |
| US20110009437A1 (en) * | 2008-02-27 | 2011-01-13 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Carboxamide-heteroaryl derivatives for the treatment of diabetes |
| US7919518B2 (en) | 2008-03-07 | 2011-04-05 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 |
| DK2262778T5 (da) | 2008-03-07 | 2020-06-08 | Acraf | 1-benzyl-3-hydroxymethylindazolderivativer og brug deraf i behandling af sygdomme baseret på ekspression af mcp-1, cx3cr1 og p40 |
| JP2011525915A (ja) * | 2008-06-26 | 2011-09-29 | アムジエン・インコーポレーテツド | キナーゼ阻害薬としてのアルキニルアルコール類 |
| US8586798B2 (en) * | 2008-07-14 | 2013-11-19 | Esionic Es, Inc. | Heat transfer medium, phosphonium ionic liquids, and methods of making |
| US8778929B2 (en) | 2008-09-29 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Substituted heteroaryl inhibitors of B-RAF |
| MX2011006555A (es) | 2008-12-19 | 2011-08-03 | Sirtris Pharmaceuticals Inc | Compuestos de tiazolopiridina moduladores de sirtuina. |
| JP5578490B2 (ja) | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| ES2618889T3 (es) * | 2009-01-14 | 2017-06-22 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para el tratamiento de trastornos inflamatorios |
| WO2010093808A1 (en) * | 2009-02-11 | 2010-08-19 | Reaction Biology Corp. | Selective kinase inhibitors |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| WO2011078221A1 (ja) | 2009-12-24 | 2011-06-30 | 味の素株式会社 | イミダゾピリダジン化合物 |
| JP5871896B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂ−ｒａｆキナーゼインヒビター |
| WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| US9120752B2 (en) | 2010-07-16 | 2015-09-01 | Purdue Pharma, L.P. | Pyridine compounds as sodium channel blockers |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| EP2691384B1 (en) | 2011-03-28 | 2016-10-26 | MEI Pharma, Inc. | (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
| KR101404151B1 (ko) * | 2011-11-25 | 2014-06-05 | 가톨릭대학교 산학협력단 | 안과 질환의 예방 및 치료용 약학 조성물 |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| WO2015104662A1 (en) | 2014-01-10 | 2015-07-16 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| NZ722019A (en) | 2014-01-13 | 2022-07-01 | Aurigene Discovery Tech Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| JP2017528471A (ja) | 2014-09-24 | 2017-09-28 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置する方法 |
| ES2842749T3 (es) | 2014-12-23 | 2021-07-14 | Gilead Sciences Inc | Procesos para preparar inhibidores de ASK1 |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| CA2977521C (en) * | 2015-02-27 | 2024-03-19 | Curtana Pharmaceuticals, Inc. | 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors |
| CN108472298B (zh) | 2015-11-24 | 2021-04-20 | 深圳阿拉丁医疗科技有限公司 | 选择性激酶抑制剂 |
| JP7028860B2 (ja) | 2016-08-26 | 2022-03-02 | カーテナ ファーマシューティカルズ，インク． | Ｏｌｉｇ２活性の阻害 |
| WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| MA46191A (fr) | 2016-09-09 | 2021-04-21 | Incyte Corp | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| IL305150B2 (en) | 2017-03-31 | 2025-03-01 | Aurigene Oncology Ltd | Compounds and preparations for the treatment of hematological disorders |
| KR20240097982A (ko) | 2017-05-23 | 2024-06-27 | 메이 파마, 아이엔씨. | 병용 요법 |
| MX2020001727A (es) | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
| EP3676264A1 (en) * | 2017-08-28 | 2020-07-08 | Acurastem Inc. | Pikfyve kinase inhibitors |
| WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
| SI3704108T1 (sl) | 2017-10-31 | 2024-07-31 | Curis, Inc. | Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka |
| SMT202200294T1 (it) | 2018-02-20 | 2022-11-18 | Incyte Corp | Derivati di n-(fenil)-2-(fenil)pirimidina-4-carbossammide e composti correlati come inibitori di hpk1 per trattare il cancro |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| EP3856348B1 (en) | 2018-09-25 | 2024-01-03 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators |
| US11427558B1 (en) | 2019-07-11 | 2022-08-30 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| MX2024003795A (es) * | 2021-09-29 | 2024-06-03 | Repare Therapeutics Inc | Compuestos de n-(5-sustituido-[(1,3,4-tiadiazolil) o (tiazolil)])(sustituido)carboxamida y uso de estos para inhibir la polimerasa theta humana. |
| CN120344522A (zh) * | 2022-09-29 | 2025-07-18 | 修复治疗公司 | N-(5-取代的-[(1,3,4-噻二唑基)或(1,3-噻唑基)](取代的)甲酰胺化合物、药物组合物以及制备酰胺化合物的方法及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59104320A (ja) * | 1982-12-06 | 1984-06-16 | Nippon Shinyaku Co Ltd | 抗アレルギ−剤 |
| US4568677A (en) * | 1983-07-23 | 1986-02-04 | Pfizer Inc. | 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents |
| US4478835A (en) * | 1983-08-02 | 1984-10-23 | Riker Laboratories, Inc. | Substituted imidazo[1,5-c]pyrimidines |
| GB8819494D0 (en) * | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
| US5051459A (en) * | 1989-03-17 | 1991-09-24 | Ciba-Geigy Corporation | N-Triazinyloxalamides |
| WO2000020402A1 (en) * | 1998-10-01 | 2000-04-13 | Astrazeneca Ab | Chemical compounds |
| ID30460A (id) | 1999-04-15 | 2001-12-06 | Bristol Myers Squibb Co | Inhibitor-inhibitor protein siklik tirosin kinase |
| JO2308B1 (en) * | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | Derivatives of phenylpyrmidine |
| JP2003502424A (ja) * | 1999-06-17 | 2003-01-21 | シオノギ バイオリサーチ コーポレイション | Ｉｌ−１２産生の阻害物質 |
| JP2001089452A (ja) * | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| US6680315B2 (en) * | 2000-06-15 | 2004-01-20 | Synta Pharmaceuticals Corp. | Triazine compounds |
| US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| PE20020870A1 (es) * | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
| AU2002334205B2 (en) * | 2001-10-26 | 2007-07-05 | Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase |
| US6693097B2 (en) * | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| MXPA04005181A (es) * | 2001-11-30 | 2005-06-17 | Synta Pharmaceuticals Corp | Compuestos de pirimidina. |
| JP2003206230A (ja) * | 2002-01-10 | 2003-07-22 | Yamanouchi Pharmaceut Co Ltd | シアノヘテロ環誘導体又はその塩 |
| AU2003284142A1 (en) * | 2002-10-15 | 2004-05-04 | Synta Pharmaceuticals Corp | Aromatic bicyclic heterocyles to modulate 1L-12 production |
| MXPA05005477A (es) * | 2002-11-21 | 2005-07-25 | Chiron Corp | Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer. |
| TW200526626A (en) * | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| US20050176767A1 (en) * | 2003-10-30 | 2005-08-11 | Laval Chan Chun Kong | Pyridine carboxamide and methods for inhibiting HIV integrase |
| WO2005046698A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| CA2545258A1 (en) * | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Pyridine compounds |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| EP1765325A4 (en) * | 2004-07-01 | 2009-08-12 | Synta Pharmaceuticals Corp | HETEROARYL COMPOUNDS SUBSTITUTED IN 2 |
| AU2005304393B2 (en) * | 2004-11-10 | 2012-09-27 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| TW200628463A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| US7923557B2 (en) * | 2004-11-10 | 2011-04-12 | Synta Pharmaceuticals Corporation | Process for preparing trisubstituted pyrimidine compounds |
-
2005
- 2005-11-10 AU AU2005304393A patent/AU2005304393B2/en not_active Ceased
- 2005-11-10 CA CA002586870A patent/CA2586870A1/en not_active Abandoned
- 2005-11-10 WO PCT/US2005/040952 patent/WO2006053227A2/en not_active Ceased
- 2005-11-10 JP JP2007541357A patent/JP2008519850A/ja active Pending
- 2005-11-10 US US11/272,509 patent/US7696202B2/en active Active
- 2005-11-10 TW TW094139373A patent/TW200628159A/zh unknown
- 2005-11-10 EP EP05820870A patent/EP1819341A4/en not_active Withdrawn
-
2010
- 2010-03-24 US US12/731,056 patent/US8236795B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008519850A5 (enExample) | ||
| AU2005304393B2 (en) | IL-12 modulatory compounds | |
| AU2005256491B2 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| US20090163708A1 (en) | Process for preparing mesylate salts of il-12 inhibitory compounds | |
| US7872005B2 (en) | 2-substituted heteroaryl compounds | |
| US7923557B2 (en) | Process for preparing trisubstituted pyrimidine compounds | |
| ES2377947T3 (es) | Compuestos de pirimidina como inhibidores de la interleucina 12 (IL-12) | |
| US20060122156A1 (en) | Heteroaryl compounds | |
| CN1656073A (zh) | 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物 | |
| JP2017537948A5 (enExample) | ||
| US20050004125A1 (en) | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | |
| CA2436659A1 (en) | Cannabinoid receptor ligands | |
| WO2003037877A1 (en) | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3β INHIBITORS | |
| EP1794156A2 (en) | Trombopoietin receptor agonists | |
| AU2005289136A1 (en) | Cyclic diarly ureas suitable as tyrosine kinase inhibitors | |
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| WO2005051366A2 (en) | Diaryl urea derivatives in the treatment of protein kinase dependent diseases | |
| JP2016175934A (ja) | フェニルアミノピリミジン化合物およびその使用 | |
| BRPI0720270A2 (pt) | Compostos basedos em 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina e processos de usos dos mesmos | |
| JP2013517273A5 (enExample) | ||
| CA2468349A1 (en) | Pyrimidine compounds | |
| CA2571019A1 (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
| JP2006501155A5 (enExample) | ||
| CA2487805A1 (en) | Peptide deformylase inhibitors | |
| JP2014513122A5 (enExample) |